Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MBX Biosciences, Inc. ( (MBX) ) just unveiled an update.
On January 11, 2026, MBX Biosciences announced it would present a 2026 outlook and business update at the 44th Annual J.P. Morgan Healthcare Conference, highlighting a strong pipeline of endocrine and metabolic programs and a solid balance sheet. The company reported that its Phase 2 Avail trial of once-weekly canvuparatide for chronic hypoparathyroidism met its primary endpoint, with one-year follow-up data slated for disclosure at a medical meeting in the second quarter of 2026 and a Phase 3 trial planned to start in the third quarter of 2026, positioning the drug as a potential best-in-class standard of care. MBX is also advancing obesity and metabolic candidates, including MBX 4291, a dual GLP-1/GIP co-agonist prodrug in Phase 1 with 12-week data expected in the fourth quarter of 2026, and plans in 2026 to nominate two additional once-monthly obesity candidates—an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist—alongside Phase 2a readouts in the second quarter of 2026 for imapextide in post-bariatric hypoglycemia. The company underscored its financial runway with preliminary, unaudited cash, cash equivalents and marketable securities of about $373.7 million as of December 31, 2025, which it expects will fund operations into 2029, providing room to execute its clinical and pipeline expansion strategy.
The most recent analyst rating on (MBX) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on MBX Biosciences, Inc. stock, see the MBX Stock Forecast page.
Spark’s Take on MBX Stock
According to Spark, TipRanks’ AI Analyst, MBX is a Neutral.
The score is held back primarily by pre-revenue status, widening losses, and accelerating cash burn, partially offset by a low-debt, strengthened balance sheet and a supportive liquidity event. Technicals are positive with the stock trading above key moving averages and a positive MACD, while valuation remains constrained by negative earnings.
To see Spark’s full report on MBX stock, click here.
More about MBX Biosciences, Inc.
MBX Biosciences, Inc., based in Carmel, Indiana, is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel precision peptide therapies via its proprietary Precision Endocrine Peptide (PEP) platform for endocrine and metabolic disorders. Its pipeline includes canvuparatide (MBX 2109) for chronic hypoparathyroidism preparing for Phase 3 development, an obesity portfolio led by MBX 4291 in Phase 1 alongside multiple discovery and preclinical obesity candidates, and imapextide (MBX 1416) in Phase 2 for post-bariatric hypoglycemia, targeting large unmet medical needs and substantial market opportunities.
Average Trading Volume: 827,096
Technical Sentiment Signal: Buy
Current Market Cap: $1.38B
Learn more about MBX stock on TipRanks’ Stock Analysis page.